2. Search Result
Search Result
Results for "

pyrimidine base

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W587907
    5-Formylcytidine

    		Biochemical Assay Reagents Others
    5-Formylcytosine is a pyrimidine nitrogen base derived from cytosine .
    5-Formylcytidine
  • HY-18622
    PP58

    		Src FGFR PDGFR Cancer
    PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values.
    PP58
  • HY-I0960
    Uracil
    3 Publications Verification

    		 Endogenous Metabolite Drug Derivative Cancer
    Uracil is a pyrimidine derivative and one of the four nucleobases in the nucleic acid of RNA. Uracil is a frequently occurring DNA base damage that results from the spontaneous or chemically induced deamination of cytosine and is mutagenic at the level of replication. Uracil could potentially alter transcriptional fidelity, resulting in production of mutant proteins .
    Uracil
  • HY-137602
    P1,P2-Diuridine-5’-diphosphate

    Up2U

    		 P2Y Receptor Others
    P1,P2-Diuridine-5’-diphosphate (Up2U) is a symmetrical dinucleoside polyphosphate containing two pyrimidine base moieties. P1,P2-Diuridine-5’-diphosphate is also an activator of purinergic P2Y receptor .
    P1,P2-Diuridine-5’-diphosphate
  • HY-161071
    Antioxidant/anticancer agent 1

    		Fungal Infection Cancer
    Antioxidant/anticancer agent 1 (compound 5) is a pyrimidine-derivatized Schiff base based on pyrimidine hydroxy-1-naphthaldehyde and has antibacterial, antioxidant, antifungal, and anticancer properties. Antioxidant/anticancer agent 1 .
    Antioxidant/anticancer agent 1
  • HY-162469
    6K465

    		Aurora Kinase c-Myc Cancer
    6K465 is a pyrimidine-based Aurora A (AURKA) inhibitor. 6K465 can reduce the levels of c-MYC and N-MYC oncoproteins, demonstrating anticancer activity .
    6K465
  • HY-139920A
    Oritinib mesylate

    SH-1028 mesylate

    		 EGFR Cancer
    Oritinib (SH-1028) mesylate is a selective, orally active, and pyrimidine-based irreversible inhibitor of EGFR with an IC50 of 18 nM. Oritinib (SH-1028) mesylate exhibits potent activity against EGFR sensitive and resistant (T790 M) mutations. Oritinib (SH-1028) mesylate significantly inhibits proliferation of tumor cells with EGFR sensitive and resistant mutation .
    Oritinib mesylate
  • HY-134369
    Ap4C tetrasodium

    		P2Y Receptor Others Inflammation/Immunology
    Ap4C tetrasodium is a dinucleoside polyphosphate containing purine and pyrimidine base moieties. Ap4C tetrasodium acts as a signaling molecule by binding to specific P2Y receptors, activating P2Y2 and P2Y4 receptors in platelets, leading to platelet aggregation and other cellular responses. Ap4C tetrasodium can be used for research in inflammation and blood coagulation .
    Ap4C tetrasodium
  • HY-W014109
    (E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione

    (E)-5-(2-Bromovinyl)uracil; BVU

    		 DNA/RNA Synthesis Infection
    (E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.
    (E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: